Comparative Pharmacology
Head-to-head clinical analysis: BETHKIS versus GENTACIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETHKIS versus GENTACIDIN.
BETHKIS vs GENTACIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
4 IU/kg (1 mg/kg) intramuscularly or subcutaneously once weekly for 4 weeks, then a maintenance dose of 2 IU/kg (0.5 mg/kg) once weekly.
5-7 mg/kg IV every 24 hours.
None Documented
None Documented
Terminal elimination half-life 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Primarily renal excretion of unchanged drug via glomerular filtration; ~90% of absorbed dose excreted in urine within 24 hours; biliary/fecal elimination <5%.
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic